Ozempic among ‘bogus’ drug patents being challenged by U.S. to spur competition

by Pelican Press
74 views 1 minutes read



Ozempic among ‘bogus’ drug patents being challenged by U.S. to spur competition


The Federal Trade Commission sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions.





Source link

#Ozempic #among #bogus #drug #patents #challenged #U.S #spur #competition

You may also like